Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide |
| |
Authors: | Robinson Ralph P Bartlett Jeremy A Bertinato Peter Bessire Andrew J Cosgrove Judith Foley Patrick M Manion Tara B Minich Martha L Ramos Brenda Reese Matthew R Schmahai Theodore J Swick Andrew G Tess David A Vaz Alfin Wolford Angela |
| |
Affiliation: | Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Groton, CT 06340, USA |
| |
Abstract: | Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4′-alkyl and 4′-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies. |
| |
Keywords: | MTP Obesity Dirlotapide Metabolite Soft drug |
本文献已被 ScienceDirect PubMed 等数据库收录! |